Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)
Ian McGowan(University of Pittsburgh), Marybeth McCauley(Family Health International 360), Kenneth H. Mayer(Miriam Hospital), Robert A. Salata(Case Western Reserve University), Leslie M Cottle, Jason E. Farley(Johns Hopkins University), Paul G. Richardson(Harvard University), Raphael J. Landovitz(APLA Health), Adriana Andrade(Johns Hopkins University), James F. Rooney(Gilead Sciences (United States)), Craig W. Hendrix(Unknown), Albert Liu(San Francisco Department of Public Health), Roy M. Gulick(New York University), Karin L. Klingman(National Institutes of Health), Ian Frank(Norwegian Womens Public Health Association), Manya Magnus(Milken Institute), Wairimu Chege(National Institutes of Health), Susan H. Eshleman(Johns Hopkins University), Mark A. Marzinke(Family Health International 360), Ying Qing Chen(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Cheryl Marcus(University of North Carolina at Chapel Hill), Joanne D. Stekler(University of Washington), P. Andrew(Family Health International 360), K. Rivet Amico(University of Cape Town), Alex R. Rinehart, Ken Ho, Alicia Young(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Jorge Santana, Timothy Wilkin(Cornell University)
Cited by 28
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
|New England Journal of Medicine|2012|3.3k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k